BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Week In Review | Jun 8, 2015
Financial News

NeoStem financial update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date announced: 2015-06-02   Note: NeoStem raised $3.8 million through the sale of 1.9 million shares at $2 to cover the overallotment...
BC Week In Review | Jun 1, 2015
Financial News

NeoStem completes follow-on

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date completed: 2015-05-27   Type: Follow-on   Raised: $25 million   Shares: 12.5 million   Price: $2   Shares after offering: 52.7...
BC Week In Review | May 25, 2015
Financial News

NeoStem financial update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date announced: 2015-05-21   Note: The California Institute of Regenerative Medicine (CIRM) awarded a $17.7 million grant to NeoStem to fund a...
BC Week In Review | May 11, 2015
Clinical News

Eltrapuldencel-T: Phase III started

NeoStem began the double-blind, international Phase III Intus trial to compare 10-20 million subcutaneous NBS20 cells vs. about 10 million subcutaneous autologous peripheral blood mononuclear cells (PBMCs) in about 250 patients. Patients will receive treatment...
BC Week In Review | May 4, 2015
Clinical News

Melapuldencel-T regulatory update

EMA classified NeoStem’s NBS20 as an advanced therapy medicinal product (ATMP). The tumor cell-specific dendritic cell therapy is in the Phase III Intus trial to treat recurrent stage III or IV metastatic melanoma. NBS20 has...
BC Week In Review | Apr 6, 2015
Clinical News

AMR-001: Additional Phase II data

Additional data from the double-blind, U.S. Phase II PreSERVE AMI trial in 161 patients diagnosed with an ST-segment elevation myocardial infarction (STEMI) showed that intracoronary AMR-001 given 5-11 days post-stent placement led to a mean...
BC Week In Review | Jan 12, 2015
Company News

NeoStem management update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service   Hired: David Mazzo as CEO and a director, formerly CEO and a director of Regado Biosciences Inc. , he succeeds Robin Smith, who remains...
BC Week In Review | Nov 24, 2014
Clinical News

NBS10: Preliminary Phase II data

Preliminary data from the double-blind, U.S. Phase II PreSERVE AMI trial in 161 patients diagnosed with an ST-segment elevation myocardial infarction (STEMI) showed that intracoronary AMR-001 given 5-11 days post-stent placement missed the primary endpoint...
BC Extra | Nov 19, 2014
Clinical News

NeoStem falls on Phase II miss

NeoStem Inc. (NASDAQ:NBS) plunged $2 (30%) to $4.78 on Tuesday after reporting that its NBS-10 stem cell therapy missed a co-primary endpoint in the Phase II PreSERVE AMI trial to treat damaged heart muscle after...
Items per page:
1 - 10 of 99
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Week In Review | Jun 8, 2015
Financial News

NeoStem financial update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date announced: 2015-06-02   Note: NeoStem raised $3.8 million through the sale of 1.9 million shares at $2 to cover the overallotment...
BC Week In Review | Jun 1, 2015
Financial News

NeoStem completes follow-on

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date completed: 2015-05-27   Type: Follow-on   Raised: $25 million   Shares: 12.5 million   Price: $2   Shares after offering: 52.7...
BC Week In Review | May 25, 2015
Financial News

NeoStem financial update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service, Cancer   Date announced: 2015-05-21   Note: The California Institute of Regenerative Medicine (CIRM) awarded a $17.7 million grant to NeoStem to fund a...
BC Week In Review | May 11, 2015
Clinical News

Eltrapuldencel-T: Phase III started

NeoStem began the double-blind, international Phase III Intus trial to compare 10-20 million subcutaneous NBS20 cells vs. about 10 million subcutaneous autologous peripheral blood mononuclear cells (PBMCs) in about 250 patients. Patients will receive treatment...
BC Week In Review | May 4, 2015
Clinical News

Melapuldencel-T regulatory update

EMA classified NeoStem’s NBS20 as an advanced therapy medicinal product (ATMP). The tumor cell-specific dendritic cell therapy is in the Phase III Intus trial to treat recurrent stage III or IV metastatic melanoma. NBS20 has...
BC Week In Review | Apr 6, 2015
Clinical News

AMR-001: Additional Phase II data

Additional data from the double-blind, U.S. Phase II PreSERVE AMI trial in 161 patients diagnosed with an ST-segment elevation myocardial infarction (STEMI) showed that intracoronary AMR-001 given 5-11 days post-stent placement led to a mean...
BC Week In Review | Jan 12, 2015
Company News

NeoStem management update

NeoStem Inc. (NASDAQ:NBS), New York, N.Y.   Business: Gene/Cell therapy, Supply/Service   Hired: David Mazzo as CEO and a director, formerly CEO and a director of Regado Biosciences Inc. , he succeeds Robin Smith, who remains...
BC Week In Review | Nov 24, 2014
Clinical News

NBS10: Preliminary Phase II data

Preliminary data from the double-blind, U.S. Phase II PreSERVE AMI trial in 161 patients diagnosed with an ST-segment elevation myocardial infarction (STEMI) showed that intracoronary AMR-001 given 5-11 days post-stent placement missed the primary endpoint...
BC Extra | Nov 19, 2014
Clinical News

NeoStem falls on Phase II miss

NeoStem Inc. (NASDAQ:NBS) plunged $2 (30%) to $4.78 on Tuesday after reporting that its NBS-10 stem cell therapy missed a co-primary endpoint in the Phase II PreSERVE AMI trial to treat damaged heart muscle after...
Items per page:
1 - 10 of 99